Roth Capital analyst Jotin Marango reiterated a Buy rating on Aptose Biosciences (NASDAQ: APTO) on June 5 and set a price target of $6. The company’s shares closed yesterday at $3.71, close to its 52-week high of $3.97.
According to TipRanks.com, Marango is a 4-star analyst with an average return of 30.9% and a 58.3% success rate. Marango covers the Healthcare sector, focusing on stocks such as Aptevo Therapeutics Inc, GlycoMimetics, and Flex Pharma.
Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $6.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.97 and a one-year low of $1.07. Currently, Aptose Biosciences has an average volume of 355.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product portfolio includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG’806.
